SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is trending as community members rally around this self-proclaimed 'chosen one' in the AI companionship space. The coin's connection to AI and a strong community are key talking points, with many expressing long-term bullish sentiment. Some users are pointing to the coin as the one to watch in the AI-driven meme coin sector.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel $INTC is trending amid speculation of a potential investment from Apple and closer collaboration between the two companies, fueling optimism about Intel's turnaround. Community members are discussing potential price targets and the impact of government support, while analysts debate the sustainability of the recent rally. Some investors believe that Intel's advanced packaging business is a key growth driver that is being overlooked.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending due to Jane Street's recent acquisition of a significant stake in the company, signaling strong institutional confidence. The community is speculating on the implications of this investment, with some suggesting a potential merger, strategic partnership, or gamma squeeze. Bullish investors are urging others to hold firm, anticipating further upward movement and a potential short squeeze.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending after positive Phase I/II data for its Huntington's disease treatment, showing a significant slowing of disease progression, although the treatment remains in early stages. The community is focused on a potential offering given the stock's surge, debating whether it's a buying opportunity or a chance to short, especially with analysts raising price targets. Discussions also involve the drug's potential market and approval timeline, with some comparing it to other biotech plays.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

IMRX is trending due to positive Phase 2a trial data for its pancreatic cancer treatment, showing a high survival rate. The community is discussing the potential for this to become a significant advancement in cancer treatment, although some are wary of potential dilution due to the company's financial situation and potential short selling.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to excitement around its potential in the quantum computing sector, fueled by recent non-dilutive funding for key technology advancements. Community members are actively discussing the stock's momentum and debating its valuation, comparing it to other quantum computing stocks and even established tech companies. Some traders express optimism about long-term growth, while others caution against a potential pullback.

Stitch Fix, Inc. engages in the provision of personalized shipments of apparel, shoes, and accessories. Its main sections are men's, kids, petite, maternity, and plus apparels. The company was founded by Katrina Lake and Erin Morrison Flynn in February 2011 and is headquartered in San Francisco, CA.

Stitch Fix Inc - Ordinary Shares - Class A

Stitch Fix Inc

Stitch Fix is trending following its Q4 earnings report, with community discussions focusing on whether the company's turnaround strategy is gaining traction and its ability to achieve future growth.  Investors are weighing the positive aspects of the report against concerns about revenue guidance and declining active clients.  Overall sentiment appears divided as some view the recent activity as a potential fade while others anticipate further gains.

TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

TNF Pharmaceuticals Inc.

TNF Pharmaceuticals is trending due to its announced shift into quantum computing and rebranding, sparking significant community discussion. While some view this pivot and associated name change as a promising move into a high-growth sector, others express skepticism, citing the company's history and concerns about potential pump-and-dump schemes. The community is actively debating the company's prospects and the potential impact of its new technology on the cryptocurrency industry.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz is trending as investors discuss its recent offering of exchangeable senior notes and a settlement distribution. Community members are debating the implications of the new debt versus the cash influx, with some eyeing a potential rally due to high short interest. Broader conversations include Hertz's leveraged position regarding interest rates and its ongoing recovery from bankruptcy.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending as traders discuss its potential to catch up with the recent gains of other Chinese tech stocks like BABA and BIDU, with some highlighting its attractive valuation and strong logistics network. Community members are actively debating potential catalysts, technical indicators, and optimal entry points, while also closely monitoring option activity and potential price targets. Despite some frustration with recent performance, there is a general sentiment of bullishness and anticipation for a breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aslan Pharmaceuticals Begins Voluntary Liquidation

Aslan Pharmaceuticals (ASLN) has released an update. Aslan Pharmaceuticals has initiated voluntary liquidation for its main operating subsidiary af...

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Short Interest Update

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN  Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 290,500...

Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders

SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...

Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Urogen Pharma (URGN) and Legend Biotech (LEGN)

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aslan Pharmaceuticals (ASLN Research Report), Urogen Pharma...

Aslan Pharmaceuticals price target lowered by $8 at H.C. Wainwright, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Aslan Pharmaceuticals price target lowered by $5 at Piper Sandler, here's why

Aslan Pharmaceuticals announces $5M registered direct offering

ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering

SAN MATEO, Calif. and SINGAPORE, March 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative...

ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

TREK-DX, the first randomized, double-blind, placebo-controlled study to be conducted in a dupilumab-experienced atopic dermatitis (AD) patient population, has started enrolling patients in the US...

ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors

New translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and...

Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which develops novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.

ASLAN Pharmaceuticals Ltd - ADR

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

ASLN
ASLAN Pharmaceuticals

Feed

News

Sentiment

Fundamentals

Info

Latest ASLN News

ASLN ASLAN Pharmaceuticals